Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates

AIDS

Volumn 21, Issue 14, 2007, Pages

  Low, Andrew J ^a,b   Dong, Winnie ^a   Chan, Dennison ^a   Sing, Tobias ^c   Swanstrom, Ronald ^d   Jensen, Mark ^e   Pillai, Satish ^f   Good, Benjamin ^a   Harrigan, P Richard ^a,b,g  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF GEORGIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

CCR5; Co receptor; CXCR4; HIV; R5; V3; Viral phenotype; X4

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; ENVELOPE PROTEIN; VIRUS PROTEIN;

ALGORITHM; AMINO ACID SEQUENCE; ARTICLE; CD4 LYMPHOCYTE COUNT; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; VIRUS ISOLATION; VIRUS LOAD;

ALGORITHMS; CD4 LYMPHOCYTE COUNT; CLONING, MOLECULAR; CROSS-SECTIONAL STUDIES; GENETIC VECTORS; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; PHENOTYPE; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

EID: 34548261959     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282ef81ea     Document Type: Article

References (38)

1. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-666.
2. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-673.
3. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272:872-877.
4. Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors-central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004; 20:111-126.
5. Zhang L, He T, Huang Y, Chen Z, Guo Y, Wu S, et al. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J Virol 1998; 72:9307-9312.
6. Schuitemaker H, Kootstra NA, de Goede RE, de Wolf F, Miedema F, Tersmette M. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol 1991; 65:356-363.
7. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992; 66:1354-1360.
8. Tersmette M, Gruters RA, de Wolf F, de Goede RE, Lange JM, Schellekens PT, et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates. J Virol 1989; 63:2118-2125.
9. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-688.
10. Mayer H, Van der Ryst E, Saag M, Clotet G, Fätkenheuer N, Clumeck N, et al. Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experiences subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial. XVI International AIDS Conference, August 13-18, Toronto, Ontario, Canada, 2006 [Abstract THLB0215].
11. Nelson M, Fätkenheuer N, Konourina I, Lazzarin A, Clumeck N, Horban A, et al. Efficacy and Safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. 14th Conference on Retroviruses and Opportunistic Infections, February 25-28, Los Angeles, California, USA, 2007 [Abstract 104aLB].
12. Lalezari J, Goodrich J, DeJesus E, Lampiris H, Gulick R, Saag M, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 Study in the US and Canada. 14th Conference on Retroviruses and Opportunistic Infections, February 25-28, Los Angeles, California, USA, 2007 [Abstract 104bLB].
13. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51:566-575.
14. Trouplin V, Salvatori F, Cappello F, Obry V, Brelot A, Heveker N, et al. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol 2001; 75:251-259.
15. Skrabal K, Low AJ, Dong W, Sing T, Cheung PK, Mammano F, et al. Determining human immunodeficiency virus coreceptor use in a clinical setting: Degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol 2007; 45:279-284.
16. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino acid substitution. J Virol 1992; 66:6777-6780.
17. Brumme ZL, Dong WW, Yip B, Wynhoven B, Hoffman NG, Swanstrom R, et al. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 2004; 18:F1-F9.
18. Jensen MA, van 't Wout AB. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003; 5:104-112.
19. Brumme ZL, Goodrich J, Mayer HB, Brumme CJ, Henrick BM, Wynhoven B, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192:466-474.
20. Fouchier RA, Brouwer M, Broersen SM, Schuitemaker H. Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J Clin Microbiol 1995; 33:906-911.
21. Resch W, Hoffman N, Swanstrom R. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001; 288:51-62.
22. Pillai S, Good B, Richman D, Corbeil J. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003; 19:145-149.
23. Sing T, Lengauer T, Beerenwinkel N, Kaiser R, Daumer M, Low A, et al. Immunological and virological parameters improve genotypic prediction of HIV-1 coreceptor usage. BioSapiens-viRgil Workshop on Bioinformatics for Infectious Diseases, September 21-23, Bonn, Germany, 2005[ Abstract 22].
24. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, He HX, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003; 77:13376-13388.
25. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-2577.
26. Edgar RC. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004; 32:1792-1797.
27. Sing T, Harrigan R, Beerenwinkel N, Daumer M, Kaiser R, Low A, et al. Immunologic markers improve genotypic prediction of HIV-1 co-receptor usage. Int Workshop on Targeting HIV Entry, December 2-3, Bethesda, Maryland, USA 2005 [Abstract 30].
28. Sing T, Harrigan R, Beerenwinkel N, Daumer M, Kaiser R, Low A, et al. Immunologic markers improve genotypic prediction of HIV-1 coreceptor usage. Keystone symposium on genome sequence variation and the inherited basis of common disease and complex traits, January 8-13, Big Sky, Montana, USA, 2006 [Abstract 30].
29. Low AJ, Brumme CJ, Brumme ZL, Hogg RS, Montaner JS, Harrigan PR, et al. Immunologic, virologic, and genotypic correlates of phenotypic CCR5/CXCR4 co-receptor usage assay readouts in a large panel of clinically derived isolates. 14th Conference on Retroviruses and Opportunistic Infections, February 25-28, Los Angeles, California, USA, 2007 [Abstract 177].
30. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993; 365:671-673.
31. Leitner T, Halapi E, Scarlatti G, Rossi P, Albert J, Fenyo EM, et al. Analysis of heterogeneous viral populations by direct DNA sequencing. BioTechniques 1993; 15:120-127.
32. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 1999; 37:2291-2296.
33. Van Laethem K, Van Vaerenbergh K, Schmit JC, Sprecher S, Hermans P, De Vroey V, et al. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr 1999; 22:107-118.
34. Lewis M, James I, Braverman M, Desany B, Jarvie T, Penny M, et al. Evaluation of an ultra-deep sequencing method to identify minority sequence variants in the HIV-1 env gene from clinical samples. 14th Conference on Retroviruses and Opportunistic Infections, February 25-28, Los Angeles, California, USA, 2007 [Abstract 680].
35. Nelson JA, Baribaud F, Edwards T, Swanstrom R. Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection. J Virol 2000; 74:8494-8501.
36. Lewis M, Simpson P, Francen S, Huang W, Whitcomb J, Mosley M, et al. CXCR4-using virus detected in patients receiving maraviroc in the Phase III studies MOTIVATE 1 and 2 originates from a preexisting minority of CXCR4-using virus. 16th International HIV Drug Resistance Workshop, June 12-16, Barbados, West Indies, 2007 [Abstract 56].
37. Roulet V, Faudon J-L, Rochas S, Labernardiere J-L, Mammano F, Level-Binay S, et al. A sensitive assay for the determination of viral tropism suitable for clinical management of HIV subtype B and non-B infected individuals treated with coreceptor antagonists: PHENOSCRIPT® ENV. 16th International HIV Drug Resistance Workshop, June 12-16, Barbados, West Indies, 2007 [Abstract 147].
38. Vandenbroucke I, Van Eygen V, Rondelez E, Van Baelen K, Styver LJ. Detection limit of X4 minority virus in abundant R5-tropic virus populations in standard genotypic and phenotypic assays. 16th International HIV Drug Resistance Workshop, June 12-16, Barbados, West Indies, 2007 [Abstract 139].